Lorlatinib with ALK + mNSCLC & encorafenib and binimetinib BRAF V600Em mNSCLC
When: Monday, October 27 | 2 p.m. EST
Presenters: Kaiwen Wang, PharmD, BCOP (The University of Texas MD Anderson) and Leila Rostamnjad, PharmD, BCOP (Dana-Farber Cancer Institute)
The treatment landscape for metastatic non–small cell lung cancer keeps evolving—and so does the evidence guiding targeted therapy decisions. This session brings together two oncology pharmacists to unpack the latest data and share how these updates translate into real-world care, from efficacy insights to AE management and dose modification.
Kaiwen Wang, PharmD, BCOP (The University of Texas MD Anderson Cancer Center) will review long-term survival and intracranial efficacy results with lorlatinib, outline common adverse events, and share practical strategies for early AE recognition, management, and dose adjustment.
Leila Rostamnjad, PharmD, BCOP (Dana-Farber Cancer Institute) will highlight new findings from the PHAROS study on encorafenib + binimetinib in BRAF V600E–mutant mNSCLC, discuss AE mitigation and patient support, and introduce NCODA’s PQI resource for optimizing supportive care and outcomes.
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Related Resources
PQI: Encorafenib (Braftovi®) and Binimetinib (Mektovi®) for the Management of NSCLC
The purpose of this PQI is to discuss the clinical considerations and general management of encorafenib and binimetinib in non-small cell lung cancer.
August 4, 2025 | 10:51 PM
Additional Upcoming Webinars
October 23, 2025 | 2:00 PM
October 27, 2025 | 2:00 PM
Upcoming Webinar
Pharmacy Perspectives: Bringing Bispecifics and 505(b)(2) Medications Into Practice
October 28, 2025 | 5:00 PM